Premium
One year's treatment of paget's disease of bone by synthetic salmon calcitonin as a nasal spray
Author(s) -
Reginster J.Y.,
JeugmansHuynen A.M.,
Albert A.,
Denis D.,
Franchimont P.
Publication year - 1988
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650030302
Subject(s) - hydroxyproline , medicine , alkaline phosphatase , creatinine , paget's disease of bone , salmon calcitonin , calcitonin , nasal spray , endocrinology , urology , chemistry , disease , enzyme , biochemistry , nasal administration , immunology
The effectiveness of synthetic salmon calcitonin (SCT) administered as a nasal spray was assessed via clinical, biological, and radiological variables in 17 previously untreated Pagetic patients over a 1‐year course of therapy. The results showed a highly significant decrease of serum alkaline phosphatase (S‐ALP) ( p < 0.05 after 1 month of treatment) and of the urinary hydroxyproline/creatinine ratio (OH/Cr) ( p < 0.01 after 1 month of treatment). For the whole group, the mean decrease in S‐ALP was 37 ± 4% (SEM) after 6 months ( p < 0.01) and 31 ± 5% after 1 year ( p < 0.01). The mean fall in OH/Cr was 35 ± 6% (SEM) ( p < 0.01) and 37 ± 7% ( p < 0.01) after 6 and 12 months, respectively. None of the usual side‐effects of SCT were reported and local tolerance was excellent throughout the study.